Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ • Healthcare

$3.63

+$0.18 (+5.5%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$3.41 - $3.7

Avg. Volume (3M)15.2M

Market Cap$1.9B

52 Week Range

$2.77$7.18

Next EarningsIn 61 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$54.8M

Net Income (TTM)

-$518.8M

EPS (TTM)

-$1.04

ROA (TTM)

-42.79%

Current Ratio

5.03

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-17.1%Q3 2025-$0.41

+5.3%Q4 2025-$0.36

+25.0%Q1 2026-$0.21

+26.7%Q2 2026-$0.22

-4.2%Q3 2026-$0.25

Nov 4

in 61 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -4.2%

Recursion Pharmaceuticals’ EPS trailed consensus in the second fiscal quarter of 2026, reported August 5, 2026, with EPS of -$0.25 versus the -$0.24 estimate (difference -$0.01) as revenue fell 59.8% year over year to roughly $7.7 million (down from about $19.1 million a year ago). The company, which is advancing a pipeline across rare disease, inflammation, and oncology programs, posted a GAAP operating loss of about $135.0 million, while net loss narrowed 23.8% year over year to around $131.0 million (from roughly $171.9 million a year ago). The EPS result likewise improved versus last year’s -$0.41, with the year-over-year change shown as +39.0%. For the next period, consensus calls for EPS of -$0.23.

View full earnings history

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that develops drug candidates across rare disease, inflammation, and oncology programs. The company remains in the clinical development stage and generated $74.7 million of revenue in FY2025, with work spanning both clinical and preclinical programs.

Name

Recursion Pharmaceuticals, Inc.

CEO

Najat Khan

Website

www.recursion.com

Industry

Healthcare

Year Founded

2013

Employees

600

Today's Snapshot

AI-generated

RXRX closed 5.5% higher at 3.63, outperforming a weaker sector. Shares changed hands at roughly twice its usual level. Recursion Pharmaceuticals is discussing a potential approval path for REC-4881, an experimental drug.

Trading Volume

Above 10d avg 15.3M

28.8M

vs S&P 500 Today

Strong Outperformance

+5.94%

Updated: September 4, 2026 at 20:02 UTC

Technical Indicators

5 Buy2 Neutral1 Sell

At 3.63, RXRX shows a short- and medium-term constructive bias even as the longer 200-day averages sit above current levels. Multiple short- and mid-term SMAs/EMAs trade below the price, supporting the near-term advance, while momentum indicators including RSI and CCI are positive and MACD has turned modestly bullish. ADX is low, indicating a weak trend, and ATR percentage is elevated but not extreme, reflecting measured volatility. OBV presents a buy signal despite a negative absolute level, and the pivot sits below the market. Technical takeaway: overall bias is Buy, led by short-term moving average strength and bullish momentum.

All signals